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ABSTRACT 
Sweden celebrated 50 years of newborn screening (NBS) in 2015 and more than 2000 infants have benefitted 
from the programme. Blood samples dried on filter paper taken at age 48 – 72 hours are sent to a centralised 
laboratory and are presently analysed for 24 different disorders, which have a better outcome if treatment is 
started as early as possible in life. For some of the disorders, early diagnosis before clinical presentation is life-
saving. 
Phenylketonuria, galactosaemia and biotinidase deficiency were the first three inborn errors of metabolism to be 
included in the Swedish programme. This thesis describes these conditions with an emphasis on screening 
performance and disease-causing genetic variants in the patients. 
Classical galactosaemia (GALT deficiency) is caused by a defect in the conversion of galactose-1-phosphate and 
UDP-glucose to glucose-1-phosphate and UDP-galactose, resulting in accumulation of toxic levels of galactose-
1-phosphate and a deficiency of UDP-galactose. Early treatment prevents severe sequelae and life-threatening 
infections. The incidence of GALT deficiency in Sweden is 1/100 000, which is lower than the reported 
incidences for other European countries. The Swedish NBS programme has high sensitivity and specificity, with 
a positive predictive value (PPV) of approximately 0.5. The increase in PPV was achieved after the decision to 
adjust the recall level in order to avoid detection of milder variants, which probably do not require treatment. 
The genetic studies revealed pathogenic variants on both alleles in all patients with GALT deficiency. Only a 
few variants were found in more than one patient, with the most cited variant, p.Gln188Arg, occurring most 
frequently. A high proportion of the variants have not been described before. Women with GALT deficiency 
who have been fortunate enough to become mothers have been recommended not to breast-feed because of the 
increase in toxic galactose metabolites seen at the end of pregnancy and after delivery. We observed the same 
increase, but the levels returned to normal within three weeks after birth in two consecutive pregnancies, in a 
woman who chose to breast-feed her babies. Our findings have been confirmed by other groups and women with 
GALT-deficiency are no longer discouraged to breast-feed. 
Phenylketonuria (PKU) is caused by a defect in the conversion of the amino acid phenylalanine (Phe) to tyrosine 
(Tyr). Without treatment, patients develop mental retardation. Inclusion of the Phe/Tyr ratio has decreased the 
number of false positive screening outcomes to the present PPV of 0.92 without any known missed cases. The 
recall levels have been lowered several times since the start of screening. An increase in the incidence of patients 
with milder disease has been observed with time. We were able to show that the impact of the adjusted recall 
levels was low. Instead, milder genetic variants, which are more common in Southern Europe, are found more 
often, which is an effect of the large number of non-Nordic immigrants who have come to Sweden during the 
last 25 years. The immigration has widened the spectrum of detected pathogenic variants. 
Biotinidase deficiency (BD) is a rare disorder affecting the recycling of the vitamin biotin. The most common 
symptoms are unspecific and progressive with eczema, hair loss and delayed psychomotor development. The 
majority of patients remained unrecognised before the introduction of screening. With NBS, the incidence of BD 
in Sweden is the same as in other Western countries (1/60 000). With adjustments of initial recall levels, virtually 
only infants with profound BD are detected in the screening programme. Disease-causing variants were detected 
in all alleles, with p.Thr532Met occurring most frequently. 
In conclusion, the Swedish screening programme for PKU, galactosaemia and BD is well-functioning with an 
internationally comparatively low rate of false positive outcomes. Future research will tell if attenuated forms of 
the disorders, that are not targets in the Swedish programme, may benefit from early detection and ought to be 
included in the programme. 
  
LIST OF SCIENTIFIC PAPERS 
I. Ohlsson A, Guthenberg C, von Döbeln U. 
Galactosemia Screening with Low False-Positive Recall Rate: The Swedish 
Experience. 
JIMD Rep. 2012; (2):113-117. 
 
II. Ohlsson A, Hunt M, von Döbeln U. 
Heterogeneity of disease-causing mutations in the Swedish classical 
galactosaemia population: Identification of fourteen novel variants. 
Manuscript 
 
III. Ohlsson A, Nasiell J, von Döbeln U. 
Pregnancy and lactation in a woman with classical galactosemia heterozygous 
for p.Q188R and p.R333W. 
JIMD. 2007; 30 (1):105 Epub 2006 Nov 30. 
 
IV. Ohlsson A, Bruhn H, Nordenström A, Zetterström R.H, Wedell A, von 
Döbeln U. 
The Spectrum of PAH Mutations and Increase in Milder Forms of 
Phenylketonuria in Sweden During 1965-2014. 
JIMD Rep. 2016 Jul 28 [Epub ahead of print] 
 
V. Ohlsson A, Guthenberg C, Holme E, von Döbeln U. 
Profound biotinidase deficiency: a rare disease among native Swedes. 
JIMD. 2010;33 (Supp 3):175-180. 
 
  
CONTENTS 
1 Introduction ..................................................................................................................... 7 
1.1 Development of newborn screening ..................................................................... 7 
1.2 Criteria for screening ............................................................................................. 8 
1.3 Newborn screening in Sweden .............................................................................. 9 
1.4 Genetics ............................................................................................................... 11 
1.5 Phenylketonuria ................................................................................................... 11 
1.5.1 From ‘Imbecillitas phenylpyruvica’ to newborn screening ................... 12 
1.5.2 Biochemistry ........................................................................................... 13 
1.5.3 Screening methods in Sweden ................................................................ 13 
1.5.4 PKU/MHP in Sweden ............................................................................. 13 
1.5.5 Symptoms, treatment and outcome ........................................................ 14 
1.5.6 Genetics ................................................................................................... 15 
1.6 Galactosaemia ...................................................................................................... 15 
1.6.2 History ..................................................................................................... 16 
1.6.3 Biochemistry ........................................................................................... 16 
1.6.4 Screening ................................................................................................. 17 
1.6.5 Symptoms, treatment and outcome ........................................................ 18 
1.6.6 Genetics ................................................................................................... 18 
1.7 Biotinidase deficiency ......................................................................................... 19 
1.7.1 History ..................................................................................................... 19 
1.7.2 Biochemistry ........................................................................................... 20 
1.7.3 Screening ................................................................................................. 21 
1.7.4 Symptoms, treatment and outcome ........................................................ 21 
1.7.5 Genetics ................................................................................................... 21 
2 Aims ............................................................................................................................... 22 
3 Subjects and methods .................................................................................................... 23 
3.1 Subjects ................................................................................................................ 23 
3.2 Present screening methods .................................................................................. 23 
3.2.1 Screening for PKU .................................................................................. 23 
3.2.2 Screening for GALT deficiency ............................................................. 24 
3.2.3 Screening for BD ..................................................................................... 24 
3.3 Genetic methods .................................................................................................. 25 
3.3.1 Sanger sequencing ................................................................................... 25 
3.3.2 Multiplex ligation-dependent probe amplification (MLPA) ................. 25 
3.3.3 Reverse transcriptase-PCR (RT-PCR) ................................................... 25 
3.3.4 Bioinformatic programmes ..................................................................... 26 
3.4 Ethical considerations .......................................................................................... 26 
4 Results ............................................................................................................................ 27 
4.1 Paper I: Galactosemia screening with low false-positive recall rate: The 
Swedish experience ............................................................................................. 27 
4.2 Paper II: Heterogeneity of disease-causing variants in the Swedish 
galactosaemia population: Identification of fourteen novel variants ................. 27 
4.3 Paper III: Pregnancy and lactation in a woman with classical galactosemia .... 28 
4.4 Paper IV: The spectrum of PAH mutations and increase of milder forms 
of phenylketonuria in Sweden during 1965 – 2014 ........................................... 29 
4.5 Paper V: Profound biotinidase deficiency – A rare disease among native 
Swedes ................................................................................................................. 30 
5 Discussion ...................................................................................................................... 31 
5.1 Paper I .................................................................................................................. 31 
5.2 Paper II ................................................................................................................. 32 
5.3 Paper III ............................................................................................................... 33 
5.4 Paper IV ............................................................................................................... 34 
5.5 Paper V ................................................................................................................ 35 
6 Conclusions ................................................................................................................... 37 
7 Clinical implications ..................................................................................................... 38 
8 Future research .............................................................................................................. 39 
9 Svensk sammanfattning ................................................................................................ 41 
10 Acknowledgements ....................................................................................................... 42 
11 References ..................................................................................................................... 44 
 
  
  
LIST OF ABBREVIATIONS 
B6-AQ Biotin-6-amidoquinoline  
BD Biotinidase deficiency 
BH4 Tetrahydrobiopterin 
BIA Bacterial inhibition assay  
BTD Biotinidase gene 
cDNA Complementary DNA, protein coding DNA 
DBS Dried blood spot 
D/G Duarte galactosaemia 
DHPR Dihydropteridine reductase 
dSNP 
ExAC 
Gal 
Database for single nucleotide polymorphisms 
Exome aggregation consortium 
Galactose 
GAL Galactosaemia caused by GALT deficiency 
GAL-DH Galactose dehydrogenase 
G-1-P Galactose-1-phosphate 
GALE Uridine diphosphate galactose-4-epimerase 
GALK Galactokinase 
GALT Galactose-1-phosphate uridyltransferase 
GALT Galactose-1-phosphate uridyltransferase gene 
GTPCH GTP cyclohydrolase 
HGMD Human gene mutation database 
LC-MS/MS Liquid chromatography and tandem mass spectrometry 
MCD 
MHP 
Multiple carboxylase deficiency 
Mild hyperphenylalaninaemia 
MLPA 
NBS 
Multiplex ligation-dependent probe amplification 
Newborn screening 
mPKU Maternal phenylketonuria syndrome 
OMIM Online mendelian inheritance in man 
PAH Phenylalanine hydroxylase 
PAH Phenylalanine hydroxylase gene 
PAHdb 
PCD 
Phe 
Phenylalanine hydroxylase locus knowledge database 
Pterin-4α-carbinolamine dehydratase 
Phenylalanine 
PKU Phenylketonuria 
POI Premature ovarian insufficiency 
PolyPhen Polymorphism phenotyping 
PPV 
RFLP 
PTPS 
RT-PCR 
SIFT 
Positive predictive value 
Restriction fragment length polymorphism 
6-pyruvoyl-tetrahydropterin synthase 
Reverse transcriptase-PCR 
Sorting intolerant from tolerant 
SNP Single nucleotide polymorphism  
Tyr Tyrosine 
  
  
  
  
  
  7 
1 INTRODUCTION 
The aim of newborn screening (NBS) is to identify infants with treatable disorders before 
they have developed irreversible symptoms. The first NBS programme was implemented in 
Massachusetts in 1963 (1). This thesis focuses on the first three inborn errors of metabolism 
to be included in the Swedish NBS programme. Although Sweden has had an NBS 
programme since 1965, little has been published about the results for these three disorders (2-
5). 
1.1 DEVELOPMENT OF NEWBORN SCREENING 
The start of the NBS era was the result of several scientific milestones, the first delivered by 
the British physician Sir Archibald E. Garrod (1857 – 1936). In his famous article ‘The 
Incidence of Alkaptonuria: A Study in Chemical Individuality”, 1908, he states that ‘certain 
hereditary disorders might be due to deficiencies of enzymes catalyzing particular steps’ – 
suggesting that they are ‘inborn errors of metabolism’ (6). 
In 1934, the Norwegian physician AsbjØrn FØlling (1888 – 1973) described the disease 
phenylketonuria (PKU), also known as FØllings disease, in a pair of siblings with mental 
retardation (7). Both children excreted large amounts of phenylpyruvic acid in the urine 
which occurs when there is a deficiency of the enzyme phenylalanine hydroxylase (PAH) that 
converts the amino acid phenylalanine (Phe) to tyrosine (Tyr). Phenylalanine accumulates 
and high levels are toxic to the developing brain, resulting in mental retardation (8). 
Treatment of the disorder was first achieved by a group led by Horst Bickel (1918 – 2000) in 
1953 (9). They developed a method to separate Phe and two other amino acids from milk 
protein, resulting in a formula with a low Phe content. The treatment did not reverse already 
developed intellectual disabilities but did improve the general well-being of the patients. 
In 1961, Robert Guthrie (1916 – 1995) developed an inexpensive, sensitive and simple 
bacterial inhibition assay which could detect elevated levels of Phe in small amounts of blood 
collected on filter paper (1). This was an important breakthrough since the test was suitable 
for mass screening of the disorder. 
When liquid chromatography tandem mass spectrometry (LC-MS/MS) was developed for 
NBS in the early 1990s a new era started (10). Previously the addition of a new disorder to 
the programme had been determined by the development of a new technique. This included 
the implementation of a new method and an increase in the amount of blood needed for the 
analysis: one disorder – one method – one aliquot of the dried blood (punched out from the 
filter paper) – one analyte – one evaluation. The introduction of MS/MS technology changed 
the conditions, from one punch – one analyte to one punch – multiple analytes and the 
possibility of including ratios between different analytes for the interpretation of results (11). 
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1.2 CRITERIA FOR SCREENING 
In 1968, Wilson and Jungner (12) formulated criteria for screening for disorders (Box 1). The 
criteria, although not specifically established for NBS, are used when a new disorder is 
evaluated for inclusion in a screening programme. 
 
 
 
 
 
 
 
 
 
Andermann revised the criteria in 2008 in order to better adapt them to the demands of today. 
They were published on The World Health Organization web page (Box 2) (13). 
 
 
 
 
 
 
 
 
 
 
The panel of disorders included in NBS programmes differs between countries. The USA has 
a panel of 34 core disorders and an additional 26 secondary disorders, which can be detected 
as a differential diagnosis of a core disorder, (http://www.hrsa.gov/ advisorycommittees/), 
(March 2015) (14). At the other extreme Finland has, until January, 2015, only screened for 
one, congenital hypothyroidism, and has now included five additional disorders in the 
Box 1: Wilson and Jungner criteria 
 
1. The condition should be an important health problem  
2. There should be an accepted treatment for patients with recognized disease  
3. Facilities for diagnosis and treatment should be available  
4. There should be a recognizable latent or early symptomatic stage  
5. There should be a suitable test or examination  
6. The test should be acceptable to the population  
7. The natural history of the condition, including development from latent to declared disease, should 
be adequately understood  
8. There should be an agreed policy on whom to treat as patients  
9. The cost of case-finding (including diagnosis and treatment of patients diagnosed) should be 
economically balanced in relation to possible expenditures on medical care as a whole  
10. Case-finding should be a continuing process and not a ‘once and for all’ project 
Wilson JMG and Jungner G 1968, Principles and practice of screening for disease, WHO Chronicle Geneva: World Health 
Organization 22:473  
 
Box 2: Updated Wilsons and Jungner criteria 
Synthesis of emerging screening criteria proposed over the past 40 years  
• The screening programme should respond to a recognized need 
• The objectives of screening should be defined at the outset  
• There should be a defined target population  
• There should be scientific evidence of screening programme effectiveness  
• The programme should integrate education, testing, clinical services and programme management  
• There should be quality assurance, with mechanisms to minimize potential risks of screening  
• The programme should ensure informed choice, confidentiality and respect for autonomy  
• The programme should promote equity and access to screening for the entire target population  
• Programme evaluation should be planned from the outset  
• The overall benefits of screening should outweigh the harm  
Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years  
Anne Andermann, Ingeborg Blancquaert, Sylvie Beauchamp, Véronique Déry Bulletin of the World Health Organization Past 
issues Volume 86: Number 4, April 2008, 241-320 
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programme (15). This illustrates the difficulties in deciding which disorders to include, and in 
Sweden we presently screen for 24 disorders (16, 17). 
When a disorder has been included in the NBS programme there is a continuous evaluation of 
the performance of the screening method. Two important factors are the sensitivity and 
specificity of the test (12). The sensitivity is a measurement of how well the test detects 
patients who have the disorder, while specificity is a measurement of how well the test 
excludes patients without the disorder. The positive predictive value (PPV) and the negative 
predictive value (NPV) represent the proportion of positive tests which are true positives and 
the proportion of negative tests which are true negatives (Figure 1) (18). 
          
  Sick Child Healthy Child 
 
  
Abnormal True Positive a False Positive b  
 
 PPV: a/(a+b) 
Normal False Negative c True Negative d  
 
NPV: d/(c+d) 
  
  
 
  
  Sensitivity:  Specificity:  
 
  
  a/(a+c) d/(b+d) 
 
  
          
Figure 1. Performance measures of screening 
1.3 NEWBORN SCREENING IN SWEDEN 
Sweden soon followed the state of Massachusetts when an NBS programme for PKU was 
initiated in 1965 by the biochemist, Hans Palmstierna (1926 – 1975). From the year 1966, all 
newborns in the country have been offered the test and the NBS programme has had a 
coverage of >98% since 1972. Hans Palmstierna also added galactosaemia to the programme 
in 1967. New tests have been developed and the number of disorders included in the 
programme is now 24 (Table 1). From the start, the programme has been voluntary and the 
present coverage is ≥99.8 %. However, the coverage amounted to only 75% during the years 
1965 – 1971. Screening for tyrosinaemia type I (1968 – 1976, 1995 – 2000) and 
homocystinuria (1967 – 1976) was tested and excluded, since the methods did not detect 
patients born with the disorders during the screening period. Histidinemia (1971 – 1972) was 
added but discontinued when it was considered to be a benign condition (19, 20). 
We have been fortunate to have a high coverage and few missed cases. It has been an 
advantage to have the screening centralised to one laboratory. This and the fact that all 
Swedish citizens are given a unique personal identification number has facilitated finding and 
keeping record of all true and false positive cases. With one centralised laboratory, it has also 
been easy to evaluate the effect of modifications of the screening methodologies.  
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Table 1. Disorders included in the present Swedish screening panel 
Type of Disorder (Method) Disorder Abbreviation Screening  
Endocrinopathies Congenital Hypothyroidism CH 1980 –  
(Immunoassays) Congenital Adrenal Hyperplasia CAH 1986 –  
        
Amino Acid Disorders Phenylketonuria PKU 1965 –  
(Tandem Mass 
Spectrometry) Homocystinuria HCY 2010 –  
  Tyrosinaemia Type 1 TYR I 2010 –  
  Argeninaemia ARG 2010 –  
  Argininosuccinic Acidaemia ASA 2010 –  
  Citrullinaemia CIT  2010 –  
  Maple Syrup Urine Diesease MSUD 2010 –  
        
Fatty Acid Disorders Carnitine Uptake Deficiency CUD 2010 –  
(Tandem Mass 
Spectrometry) Carnitine Palmitoyl Transferase Deficiency I CPT I  2010 –  
  Carnitine Acylcarnitine Translocase Deficiency CACT 2010 –  
  Carnitine Palmitoyl Transferase Deficiency II CPT II 2010 –  
  Medium-Chain Acyl-CoA Dehydrogenase Deficiency MCAD 2010 –  
  Very Long-Chain Acyl-CoA Dehydrogenase Deficiency  VLCAD 2010 –  
  Multiple Acyl-CoA Dehydrogenase Deficiency MAD 2010 –  
  
Long-Chain 3-Hydroxy-Acyl-CoA Dehydrogenase 
Deficiency/Mitochondrial Trifunctional Protein Deficiency 
LCHAD/TFP 2010 –  
        
Organic Acid Disorders Propionic Acidaemia PROP 2010 –  
(Tandem Mass 
Spectrometry) Methylmalonic Acidaemia/Cobalamin Disorders MMA/Cbl 2010 –  
  Isovaleric Acidaemia  IVA 2010 –  
  Beta-Ketothiolase Deficiency  BKT 2010 –  
  Glutaric Acidaemia Type I GAI 2010 –  
        
Other Disorders Classical Galactosaemia GAL 1967 –  
(Enzyme Assays) Biotinidase Deficiency  BD 2002 –  
 
The screening procedure consists of: information to parents pre- and post delivery, sampling, 
analyses, a data report and follow-up. Prior to sampling, the parents are given a pamphlet at 
the maternity clinic explaining the purpose of the test. Information is given a second time by 
the midwife in connection with the sampling in both written text and orally. The sample is 
taken as soon as possible after 48 hours of age, and preferably before 72 hours. The timing 
has undergone several changes since the start of screening, when the test was taken between 4 
and 6 days of age, until today’s recommendation of 48 hours. 
The NBS test has several names: the Guthrie test (after Robert Guthrie), the PKU-test (after 
the first disorder to be included in the programme) and the heel prick test (since the sample is 
taken from the heel of the newborn in most countries). The latter is not practised in Sweden 
because venous blood taken from the back of the hand has been found to be less painful (21, 
22). 
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The samples are sent to the screening laboratory in pre-addressed envelopes by ordinary post, 
and the laboratory is only open on weekdays. All samples are processed the same day they 
arrive, which is at an average age of 5.5 days. Screening for classical galactosaemia is 
performed the same day the samples arrive and infants with a positive test are recalled 
immediately. The other screening tests are run over night and evaluated the following day. 
Positive cases are reported by phone and letter and, after a clinical investigation, the 
screening laboratory receives reports on the outcome. Normal results are sent by post to the 
referring maternity ward. 
1.4 GENETICS 
Phenylketonuria (PKU, OMIM #261600), classical galactosaemia (GAL, OMIM #230400) 
and biotinidase deficiency (BD, OMIM#253260) are monogenic disorders, inherited in an 
autosomal recessive mode. All three disorders meet the Swedish definition of a rare disorder 
defined as affecting less than 1/10 000, respectively (http://www.socialstyrelsen.se/ 
rarediseases/aboutrarediseases). Disease-causing variants can be divided into missense (non-
synonymous and nonsense), synonymous, splice site, deletions, insertions and 
insertion/deletions. A large number of disease-causing variants have been described in each 
responsible gene: phenylalanine hydroxylase (PAH, EC 1.14.16.1), galactose-1-phosphate 
uridyltransferase (GALT, EC 2.7.7.10) and biotinidase (BTD, EC 3.5.1.12), resulting in a 
continuum of severities of clinical disease. The most frequently occurring variants are non-
synonymous substitutions which alter the amino acid sequence of the protein. Non-
synonymous variants comprise approximately 71% of all reported variants for the three 
genes, as depicted in HGMD® Professional 2016.2 (https://portal.biobase-international. 
com/hgmd/pro/start.php). 
An increased incidence in autosomal recessive disorders is seen in some populations. This 
can be the effect of a high rate of consanguineous marriages, founder effect, genetic drift or 
different combinations of all three (23, 24). One example is the Irish Travellers where several 
rare metabolic disorders have a higher incidence than otherwise reported, including GALT 
deficiency (≈1/450) and PKU (≈1/800) (23, 25). Programmes have been established for 
carrier screening for a limited number of rare genetic disorders in some specific populations 
(26, 27). 
1.5 PHENYLKETONURIA 
PKU and the attenuated variant, mild hyperphenylalaninaemia (MHP), is one of the most 
common autosomal recessive metabolic disorders with an incidence of 1/10 000 – 1/15 000 in 
large parts of Europe and the USA (28). Higher incidences are observed where consanguinity 
is common (e.g., Turkey and the Middle East, 1/2600 – 6500) (29). In Japan and Finland the 
incidence is much lower, 1/125 000 – 1/200 000 (30-32). Finland has therefore sent samples 
to Sweden from newborns of immigrants (high-risk screening) (15). 
PKU and MHP are caused by a deficiency of the liver enzyme, phenylalanine hydroxylase 
(PAH) which catalyses the conversion of the amino acid Phe to Tyr with tetrahydrobiopterin 
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(BH4) as co-factor. In all patients with elevated Phe, a co-factor deficiency must be ruled out. 
This is caused by a defect in one of the enzymes in the biosynthesis or recycling of BH4: GTP 
cyclohydrolase I (GTPCH, EC 3.5.4.16), 6-pyruvoyl-tetrahydropterin synthase (PTPS, EC 
4.2.3.12), pterin-4α-carbinolamine dehydratase (PCD, EC 4.2.1.96) or dihydropteridine 
reductase (DHPR, EC 1.5.1.34) (33). The prevalence of co-factor deficiencies is about 1 – 
2% of newborns with a defect in the conversion of Phe to Tyr (34). Some of these patients 
can be missed because of normal Phe values in the neonatal period (35). 
1.5.1 From ‘Imbecillitas phenylpyruvica’ to newborn screening 
AsbjØrn FØlling described 10 patients who were mentally retarded and excreted 
phenylpyruvic acid in the urine. He called the disorder ‘Imbecillitas phenylpyruvica’(36, 
37). The following year, Penrose was able to show that PKU is a recessively inherited 
disease (38). In 1937, Jervis described the features of 50 cases with phenylpyruvic acid in 
the urine. The most common clinical symptoms were: pronounced intellectual defects, 
abnormal behaviour or apathy, hyperactivity of the deep reflexes, anomalies of the motor 
system, seizures, blue eyes, eczema, pale delicate skin and blond hair (39). Later the same 
year, Penrose and Quastel showed that excretion of phenylketones was correlated with the 
intake of Phe in the patients (40). Ten years later, Jervis described the metabolic block and 
enzymatic deficiency (8). In 1953, the first patient with PKU was treated with a diet low in 
Phe resulting in improvement both biochemically and in mental health (9). Dr Centerwalls 
developed a diagnostic test in which a solution of ferric chloride was applied on a wet diaper. 
A green colour appeared when phenylpyruvic acid was present: – the diaper test (41). Robert 
Guthrie had become interested in PKU when his niece was diagnosed with the disorder. In 
1958, he developed a bacterial inhibition assay for monitoring Phe in treated PKU patients 
(42). The assay was to become the first screening method in NBS when Guthrie and Susi 
modified it, in 1961, to be used with whole blood collected on filter paper (Guthrie cards), a 
sampling procedure still in use (Table 2) (42). 
Table 2. History of phenylketonuria 
 
 
 
 
 
 
 
References: (1, 8, 9, 37, 38, 41-44) 
History of phenylketonuria 
1934 – First cases of ‘Imbecillitas phenylpyruvica’ were described (FØlling)  
1935 – Recessive inheritance was reported (Penrose)  
1947 – The enzyme block was identified (Jervis)  
1953 – Dietary treatment was introduced (Bickel)  
1957 – The diaper test for phenylketones was developed (Centerwalls) 
1958 – The bacterial inhibition test was developed (Guthrie)  
1961 – NBS started (Guthrie and Susi)  
1965 – NBS started in Sweden  
1985 – The cDNA for PAH was cloned and characterised (Woo)  
1986 – The entire gene was sequenced (DiLella)  
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1.5.2 Biochemistry 
Phenylalanine is an essential amino acid, mainly metabolised in the liver. Tetrahydrobiopterin 
(BH4) is the hydrogen donor for the hydroxylation of Phe to Tyr (Figure 2). This co-factor is 
also required for other hydroxylations important for the production of dopamine, 
catecholamines, melanin, serotonin and nitric oxide (45).  
 
 
 
 
 
 
Figure 2. The metabolic defect in PKU 
1.5.3 Screening methods in Sweden 
The first screening method for PKU/MHP screening in Sweden was the semi-quantitative 
bacterial assay from the early 1960s (1). The initial recall level was 6 mg% (360 µmol/l) 
lowered to 4 mg% (250 µmol/l) in 1976. From 1978 onwards, all positive samples in the 
bacterial assay were subjected to ion-exchange chromatography (Liquimat®) as a second-tier 
method. Fifteen years later, an HPLC method for second-tier use was introduced. The further 
development of the methods is described in Table 1, Paper IV. After a period of 
determination of Phe by an enzymatic assay (Quantase®), the present technique, LC-MS/MS, 
was implemented in 2005 (46). 
 
1.5.4 PKU/MHP in Sweden 
Patients are categorised according to the level of Phe in the blood spot taken when the patient 
is recalled for clinical evaluation and the start of treatment. The classification employed in 
this thesis is classical PKU: Phe >1200 µmol/l, mild PKU: Phe 500 – 1200 µmol/l and MHP: 
Phe 180 – 500 µmol/l. From 1965 to1979, samples were to be taken on days 4 – 6 after birth. 
Screening samples taken earlier were rejected (5). The goal was to have infants recalled and 
retested within 10 days of age. After 1979, the recommended sampling time was as soon as 
possible after 72 hours, and this was moved forward in 2008 to 48 hours, when plans for 
expanded screening with MS/MS technology had started. The mean age at sampling is now 
2.7 days and treatment is initiated before age 7 days. 
Phenylalanine Tyrosine 
Protein 
Phenylpyruvate 
Phenylacetate 
Phenyllactate 
PAH 
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1.5.5 Symptoms, treatment and outcome 
Untreated classical PKU leads to a progressive intellectual disability during childhood and 
the teenages and there can be a phenotypic variation between patients with the same genotype 
(47-49). A follow-up study of 46 untreated adult PKU patients did not demonstrate any 
progressive loss of abilities after 20 years in 41 patients (Figure 3) (50). 
The treatment comprises a diet low in Phe (low amount of natural protein), supplemented 
with the other amino acids, vitamins, co-
factors and trace elements (51, 52). Normal 
development is achieved when treatment is 
initiated within the first weeks of life.  
Women with untreated or poorly controlled 
PKU are at risk of having an offspring with 
the maternal PKU syndrome (mPKU) (53-
56). Clinical symptoms of mPKU are: an 
increased frequency of congenital heart 
disease, microcephaly, intrauterine growth 
retardation and mental retardation. 
Spontaneous miscarriages are also more 
common (57). Not only children of women 
with classical PKU, but also those of women 
with less severe PKU are at risk, since Phe 
levels are higher in the foetus compared                     Figure 3. Symptoms in PKU                  
to the mother. This is due to a placental gradient favouring the foetus, thereby increasing the 
Phe concentration by 70–80% (58). The mPKU syndrome has been known since the late 
1950s when several women with PKU gave birth to mentally retarded children (59). 
The implementation of treatment with the synthetic form of tetrahydrobiopterin (BH4), 
Sapropterin dihydrochloride (Kuvan ®, Bio Marin, CA, USA), is an important 
advancement (60). It results in a relaxation of the diet for many patients. Treatment with 
pegylated phenylalanine ammonia lyase, administration of large neutral amino acid 
mixtures, glycomacropeptides (a protein low in Phe), chemical chaperones, gene-therapy 
including nonsense read through technology and genetically modified probiotics are under 
investigation (61-64). 
The patients are treated at one of five metabolic centres located at the university hospitals in 
Malmö/Lund, Göteborg, Stockholm, Uppsala and Umeå. Newborns, younger children and 
women who are, or plan to become pregnant have a more intensive contact and test schedule. 
The target level of Phe has varied throughout the years. Until 1986, treatment was initiated at 
pre-treatment Phe values >500 µmol/l. Most guidelines today recommend Phe concentrations 
that are stable over time and below 360 µmol/l in younger children, but for older patients it 
varies substantially (65-67). In Sweden the targets are: 120 – 300 µmol/l (0 – 1 year), 120 – 
Child/Adult 
• Fair skin and hair 
• Eczema 
• Mental retardation 
• Behavioural, emotional and social 
problems 
• Hyperactivity 
• Psychiatric problems 
• Neurological symptoms 
Maternal 
PKU 
syndrome 
• Misscarriage 
• Low birth weight 
• Microcephaly 
• Heart defects 
• Delayed development 
• Behavioural problems 
• Intellectual disabilty 
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400 µmol/l (1 – 10 years) and 120 – 500 µmol/l (>10 years), and for pregnant women 100 – 
300 µmol/l. 
The majority of patients detected by screening have adhered to the treatment and have a 
normal development. 
1.5.6 Genetics 
The PAH -gene is 90 kbp long and located on chromosome 12q.23.2 and has 13 exons 
encoding 452 amino acids (44, 68). To date, 893 pathogenic variants have been described in 
HGMD® Professional 2016.2, while the Phenylalanine Hydroxylase Locus Knowledge 
Database (PAHdb, http://www.pahdb.mcgill.ca) includes fewer variants. An advantage of the 
PAHdb, although it is not complete, is that it includes in vitro expression analyses and 
genotype-phenotype correlations (69). Several studies have indicated that the spectrum of 
PAH variants differs between various populations, and that the number of different variants in 
a given population usually is high, with a few being prevalent and a large number being 
private variants (70). Common variants in Scandinavia are c.1315+1G>A, p.Arg408Trp and 
p.Tyr414Cys, the first two being associated with classical PKU and the latter with mild PKU 
(4, 71, 72). 
1.6 GALACTOSAEMIA 
The term galactosaemia includes three different enzyme deficiencies, galactokinase (GALK, 
EC 2.7.1.6), galactose-1-phosphate uridyltransferase (GALT) and uridine diphosphate 
galactose 4-epimerase (GALE, EC 5.1.3.2) deficiency (73). Defects of the enzymes GALK 
and GALE are extremely rare. GALT deficiency, usually referred to as classical 
galactosaemia (GAL), is more common, with an average worldwide incidence of 1/30 000 – 
1/40 000 (74). The incidence is as high as 1/480 in the Irish Traveller Community and 
extremely low in Japan, 1/1 000 000 (25, 75). 
1.6.1.1 Galactokinase deficiency 
Galactokinase deficiency (GALK) is caused by a block in the first step of the galactose 
pathway, resulting in accumulation of Gal and galactitol. The main clinical symptom is 
cataracts, which are usually bilateral (76). By initiating treatment with a galactose-free diet 
within the first 4 – 8 weeks of life, the cataracts may be reversible (77). GALK deficiency 
will not be discussed further here. 
1.6.1.2 Galactose-1-phosphate uridyltransferase deficiency  
Galactose-1-phosphate uridyltransferase (GALT) catalyses the conversion of galactose-1-
phosphate and UDP-glucose to glucose-1-phosphate and UDP-galactose. In GALT 
deficiency this is compromised, leading to an accumulation of galactose (Gal), galactose-1-
phosphate (G-1-P), galactitol and galactonate. The result is also a reduction in the levels of 
UDP-galactose. In classical galactosaemia there is a total loss of enzyme activity but 
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attenuated forms exist with rest activity of the enzyme (78, 79). The disorder is detected 
through the Swedish NBS programme and is discussed further in this thesis. 
1.6.1.3 Uridine diphosphate galactose 4-epimerase deficiency  
The third step in the pathway is the conversion of UDP-galactose to UDP-glucose, catalysed 
by GALE. The deficiency is extremely rare with severities from a mild form, limited to 
leukocytes and erythrocytes, to a generalised disease with a severe prognosis (80). The 
disorder will not be discussed further here. 
1.6.2 History 
Galactosaemia (GALT deficiency) was first described in 1908, by von Reuss (81). The first 
patient was treated with a galactose restricted diet in 1935 (82) and NBS was initiated in 1964 
(83, 84). Galactosaemia has not, however, been the same success story as PKU, since the 
majority of patients exhibit long-term complications of various severities despite an early 
start of treatment. The complications extend from shyness and speech difficulties to mental 
retardation and peripheral neuropathy. Approximately 80% of females develop ovarian 
insufficiency and infertility (Table 3) (85). 
Table 3. History of galactosaemia 
 
 
 
 
 
 
 
 
 References: (1, 81, 82, 85-91) 
1.6.3 Biochemistry 
The galactose pathway, also known as the Leloir pathway, metabolises galactose to glucose-
1-phosphate, which is further metabolised to glucose-6-phosphate (91). Simultaneously, 
UDP-glucose is converted to UDP-galactose in the reaction. In GALT deficiency, there is an 
accumulation of Gal, G-1-P and galactitol in the body when the newborn is fed milk. The 
defect also leads to disturbed protein and lipid glycosylation (Figure 4) (92-95). 
 
History of galactosaemia 
1908 – The first case was described (von Reuss) 
1917 – Inheritance was established (Goppert) 
1935 – Treatment with a milk free diet was reported (Mason and Turner) 
1956 – The enzyme block was identified (Kalckar) 
1956 – Accumulation of galactose-1-phosphate was found (Schwarz) 
1964 – NBS for galactosemia was developed (Guthrie and Susi) 
1967 – NBS started in Sweden 
1984 – Long-term complications were reported (Gitzelmann) 
1988 – The cDNA for GALT was cloned and characterised (Reichardt and Berg) 
1990 – The largest study of long-term outcome was published (Waggoner)  
1992 – The entire gene was sequenced (Leslie) 
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Figure 4. The biochemistry of GALT deficiency 
 
1.6.4 Screening 
The first screening method for galactosaemia was a bacterial inhibition assay which utilised a 
GALT-lacking E. coli strain (1). This could not metabolise Gal, resulting in cell death in the 
presence of a high concentration of Gal or G-1-P. A clear zone, around the newborn blood 
specimen with elevated Gal and/or G-1-P, is 
seen in the bacterial growth on an agar plate. 
A semi-quantitative determination of the 
GALT enzyme, called the Beutler test, is 
used today (78). The glucose-1-phosphate 
produced by the galactose-1-phosphate-
uridyltransferase reaction is converted to 
glucose-6-phosphate. Glucose-6-phosphate 
is then oxidised by glucose-6-phosphate 
dehydrogenase with NADP
+ 
as hydrogen 
acceptor. NADPH is detected by emission of 
fluorescence in UV -light (Figure 9). 
                             
Figure 5. Symptoms in galactosaemia
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• Elevated  galactose-1-phosphate 
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• Growth delay 
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• Speech difficulties 
Adult 
• Progressive ataxia 
• Tremor 
• Infertility (females) 
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1.6.5 Symptoms, treatment and outcome 
A lactose and galactose-restricted diet was introduced in 1935 (82). When galactosaemia is 
suspected in a newborn, prompt withdrawal of milk (galactose) is necessary since the acute 
disorder is life-threatening. Appropriate treatment of clinical signs, such as hypoglycaemia, 
anaemia, sepsis, hyperbilirubinaemia and coagulation disorder, reverses most of the 
symptoms. A galactose-free diet lowers, but does not normalise, the levels of Gal, G-1-P and 
galactitol. In spite of early initiation of treatment and good compliance the majority of the 
patients exhibit long-term deficits (Figure 5), and this includes younger siblings who have 
been treated since birth (85, 96, 97). 
1.6.6 Genetics 
The GALT gene is located at chromosome 9p13 (98). The entire gene was sequenced in 1992 
(90). The cDNA is 1295 bases long and codes for 379 amino acids and the enzyme protein is 
a dimer of two identical subunits (99). 
The HGMD® Professional 2016.2 now includes 319 mutations. The majority of these are 
missense/nonsense variants (79%). A few variants make up for approximately 80% of all 
mutated alleles, of which p.Gln188Arg, p.Lys285Asn and p.Ser135Leu are associated with 
classical galactosaemia, while p.Asn314Asp gives a less severe variant (100). 
The most common pathogenic variant in the GALT gene in European populations or 
individuals of European descent is the missense variant, p.Gln188Arg in exon 6. It accounts 
for approximately 60% of all mutated alleles in these populations. The highest frequency is 
found in Western Europe, in the Republic of Ireland and the British Isles. In other 
populations, it is very rare, such as Native Americans, Jews, East Indians, Japanese and 
Pakistani (101, 102). The amino acid exchange is located in a highly conserved domain of the 
GALT protein, only two amino acids from the active site, histidine-proline-histidine (103). 
Expression analyses of the p.Gln188Arg variant in COS cells, have shown a reduced GALT 
activity to about 10% of normal, but later, when studies in a yeast expression system, which 
completely lacks endogenous GALT, less than 1% of wild-type activity was found. Elsevier 
and Fridovich-Keil found that the heterodimer p.[Gln188Arg];[=], exhibits 15% wild-type 
activity while another heterodimer p.[Arg333Trp];[=], exhibits 50% wild-type activity, 
suggesting that the p.Gln188Arg variant exerts a negative effect on the adjacent subunit (104, 
105). 
The variant, p.Asn314Asp, in exon 10, is associated with a variant of galactosaemia called 
Duarte (79) and was first reported as a polymorphism (106). It is a common variant in many 
populations with an incidence of 6 – 7% in Europeans (107). There are two variants of 
Duarte, Duarte-1 (Los Angeles variant) and Duarte-2 (Duarte). Duarte-1 expresses 100 – 
110% of normal GALT activity in red blood cells and carries a silent variant, p.Leu218Leu, 
in exon 7, in addition to p.Asn314Asp. The Duarte-2 variant expresses approximately 50% of 
normal GALT activity and is in linkage disequilibrium with the promoter deletion c.-119_-
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116delGTCA and the intron variants, c.378-27 G>C, c.503-24 G>A and c.507+62G>A. 
Heterozygotes for one classical galactosaemia allele (G) and one Duarte-2 allele (D) have 
approximately 25% of normal GALT activity in erythrocytes (108, 109). 
 
1.7 BIOTINIDASE DEFICIENCY 
Biotin cannot be synthesised by humans (110). The vitamin is a co-factor for formation of 
holocarboxylase, deficient in multiple carboxylase deficiency (MCD) (111).There are two 
variants of MCD: the neonatal form in which the common presenting symptoms are 
vomiting, lethargy and hypotonia, and the late-onset or juvenile form which is characterised 
by skin rash, conjunctivitis, alopecia, ataxia and, occasionally, candida infections and 
developmental delay. It was not until 1981, that researchers realised that late-onset multiple 
carboxylase deficiency and the neonatal form were two separate disorders, the latter caused 
by a defect in the enzyme holocarboxylase synthetase (EC 6.3.4.10) and the former in 
biotinidase (112-114). 
Healthy persons can become biotin-depleted from the intake of large amounts of raw eggs. 
Raw egg white contains avidin which binds biotin and decreases the bioavailability of the 
vitamin (115, 116). 
1.7.1 History 
It was quite recently that biotinidase deficiency was detected. The enzyme was first described 
in animals in 1965, and it took almost 20 years until the first patient was identified and treated 
with biotin. Soon after that NBS was in place (Table 4).  
Table 4. History of biotinidase deficiency 
 
 
 
 
 
 
References: (117-122) 
 
 
 
History of biotinidase 
1965 – The enzyme was described in animals (Pispa)  
1983 – The enzyme defect was identified in a patient and treatment implemented (Wolf)   
1984 – NBS was developed (Heard)  
1985 – The enzyme was purified (Craft)  
1994 – The cDNA was cloned and characterised (Cole)  
1998 – The structure of the gene was described (Knight)  
2002 – Newborn screening started in Sweden 
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1.7.2 Biochemistry 
Biotinidase catalyses the release of biotin from dietary protein. Biotin is the co-factor of four 
carboxylases: acetyl-CoA carboxylase (EC 6.4.1.2), propionyl-CoA carboxylase (EC 6.4.1.3), 
β-methylcrotonyl-CoA carboxylase (EC 6.4.1.4) and pyruvate carboxylase (EC 6.4.1.1), 
involved in the synthesis of fatty acids, the catabolism of branched chain amino acids or 
gluconeogenesis (123). Almost all dietary biotin is bound to lysine residues in proteins. This 
is cleaved into biocytin which is a biotin-lysine complex. Biotin is released from lysine by 
biotinidase and used for the formation of holocarboxylase (Figure 6) (124). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein catabolism   Fatty acids synthesis   Gluconeogenesis 
 
Figure 6. The biotin cycle 
Biotin 
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Active holocarboxylases 
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1.7.3 Screening  
Newborn screening was implemented soon after the identification of the disorder and spread 
to many countries (125). A colometric method was used initially, based on the conversion of 
n-biotinyl-para-aminobenzoate to para-aminobenzoate, which is quantified by 
spectrophotometry (119). Before the start of screening, the disorder was thought to be 
extremely rare. It is more common in some countries with a high rate of consanguineous 
marriages (126). With NBS, a new group of patients was recognised – those with partial BD 
with a biotinidase activity of 10 – 30% of normal (127). 
 
1.7.4 Symptoms, treatment and 
outcome 
Untreated patients with profound BD can 
develop severe irreversible symptoms, such as 
mental retardation and hearing loss (Figure 7). 
Symptoms can appear at any age, from infancy 
to adulthood (128, 129). Patients remain 
asymptomatic with an early start of treatment 
with 5 – 10 mg of biotin daily (130). It is not yet 
known if individuals with partial BD require 
treatment. Isolated cases have been described, in 
which patients have exhibited symptoms during 
metabolic stress (131-134). 
 
Figure 7. Symptoms in BD 
1.7.5 Genetics 
The biotinidase (BTD) gene is located on chromosome 3q25 (135). The protein coding DNA 
(cDNA) was first cloned and characterised in 1994 and consists of four exons and encodes 
for 543 amino acids (121). The majority of pathogenic variants are located in exon 4. 
There are two databases for variants in the biotinidase gene, HGMD® Professional 2016.2, 
which describes 219 variants and the BTD database at Arup Laboratories 
(http://www.arup.utah.edu/database/BTD/BTD_welcome.php) with 204 variants. 
The genetics in BD is somewhat special. Pathogenic variants detected in clinically diagnosed 
patients differ from those in patients identified by NBS. The most frequent variant in 
symptomatic patients is a frameshift c.98_104delinsTTC (p.Cys33fs). Common variants in 
the NBS group are, among others, p.Gln456His and p.[Ala171Thr;Asp444His] (136, 137). 
Patients with partial BD almost universally carry p.Asp444His on at least one allele (138). 
Profound 
biotinidase 
deficiency 
•Seizures 
•Hypotonia 
•Hearing and vision loss 
•Respiratory problems 
•Ataxia 
•Skin rash 
•Alopecia 
•Candida infections 
Partial 
biotinidase 
deficiency 
•Hypotonia? 
•Skin rash? 
•Alopecia? 
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2 AIMS 
Sweden is one of the countries in the world with the longest tradition of NBS. The overall 
aim of this thesis was to describe the development of NBS in Sweden, from 1965 until today, 
with a focus on the results for the first three metabolic disorders to be included in the 
programme: PKU, galactosaemia and BD.  
The specific aims were: 
- To implement molecular methods for GALT and BTD 
- To determine disease-causing genetic variants in Swedish patients with PKU, GALT 
deficiency and BD 
- To investigate the outcome and peformance of neonatal screening for PKU, 
galactosaemia and BD in Sweden 
- To investigate the effect of breast-feeding in a woman with classical galactosaemia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  23 
3 SUBJECTS AND METHODS 
Newborn screening for PKU, galactosaemia and BD in Sweden has been continued since 
starting in 1965, 1967 and 2002, respectively. Data on the number of screened newborns and 
immigrant children, as well as positive and false positive cases, have been collected 
prospectively. 
3.1 SUBJECTS 
Papers I and IV, describe the results of the screening programme for galactosaemia and PKU. 
A total of 4 401 900 newborns were screened for galactosaemia (1967 – 2010) and 4 969 200 
newborns for PKU (1965 – 2014), respectively. Screening for BD covered 637 500 newborns 
(2002 – 2008, Paper V). In Paper II, a larger cohort of 4 976 700 newborns from the years 
1967 – 2010, had been screened. The number of screened immigrant children under the age 
of 18 is only available for the BD (n=5100). Data were compiled retrospectively.  
In Papers II, IV and V we describe the genetic studies which were performed in the majority 
of confirmed cases. Only index cases were included in the calculations of the allele 
frequencies. 
One patient with galactosaemia was investigated in more detail in Paper III. 
3.2 PRESENT SCREENING METHODS 
The initial screening methods for PKU and galactosaemia were the Guthrie bacterial 
inhibition assays. For PKU, this was followed by the Quantase® enzymatic assay (139) 
before the present LC-MS/MS technology was implemented. For galactosaemia the bacterial 
assay was exchanged with the Beutler test, which is still in use with slight modification. 
3.2.1 Screening for PKU 
LS-MS/MS technology is a high-resolution technique for simultaneous quantification of 
multiple metabolites. This rapid and sensitive technique is based on the mass-to-charge ratio 
(m/z ratio) of ions (140). In NBS, an extraction solution, including internal standards, is added 
to the dried blood spot (DBS). After incubation, the solution is injected by electrospray into 
the ion source. Molecular ions are separated in the first mass spectrometer according to their 
m/z ratio. Ions of interest are fragmented in the collision cell, followed by a second separation 
according to their m/z ratio in the second mass spectrometer (Figure 8) (140, 141). Targeted 
metabolites are evaluated with the Specimen Gate Laboratory Software (PerkinElmer®). The 
total number of metabolites measured is 44 and 44 ratios are calculated and also used for the 
interpretation. For PKU this includes Phe and Tyr and the ratio Phe/Tyr (10). LC-MS/MS 
was implemented in 2005, using an in-house method, which was replaced in 2008 by the 
NeoBase™ non-derivatized assay solution (Perkin Elmer®, Finland).  
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Figure 8. Principle of LC-MS/MS technology 
 
3.2.2 Screening for GALT deficiency 
In the Beutler test G-1-P is converted to gluconate-6-P and NADPH
+
,
 
which is estimated by 
measuring the fluorescence in a multi-plate reader (Figure 9) (78). Until 2015, the 
fluorescence was estimated visually under a UV -lamp (described in detail in Paper I), 
whereafter the evaluation is performed on a Wallac Victor
2
 Multilabel Plate Reader 
(PerkinElmer®, Finland) for improved accuracy. Gal and G-1-P are determined 
quantitatively as the second tier in positive samples (142). 
 
 
 
 
PGM: Phosphoglucomutase (E.C. 5.4.2.2), G6P-DH: Glucose-6-phosphat dehydrogenase (E.C. 1.1.1.49) 
Figure 9. Principle of the Beutler assay 
 
Newborns with an activity of ≤10% are reanalysed in quadruplets using the Beutler method 
and determinations of total Gal, as described in Paper I. Presently, all newborns with an 
activity of ≤10% are recalled regardless of total Gal. 
3.2.3 Screening for BD 
Biotinidase activity is determined by a semi-quantitative, enzymatic assay using biotin 6-
amidoquinoline (B6-AQ) as substrate and fluorometric quantification of the released 6- 
amidoquinoline (Figure 10) (143). 
 
 
 
Figure 10. Principle of the biotinidase assay 
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Glucose-6-P + NADP
+ 
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The initial recall level was ≤25% of the mean activity of samples analysed the same day. This 
was lowered to ≤20% in 2006. In recalled patients, the quantitative determination of 
biotinidase activity is performed in plasma with the same substrate (143). 
 
3.3 GENETIC METHODS 
3.3.1 Sanger sequencing 
Sanger sequencing (144), the most specific and accurate method for identifying single base 
substitutions (point mutations) or small insertions or deletions, was used. The PAH gene was 
routinely sequenced at the laboratory prior to the start of this thesis while methods for GALT 
and BTD sequencing were being implemented by us (Papers II, IV, V). 
Primers were designed for PCR amplification and sequencing of all exons and including at 
least 30 nucleotides of the intronic sequences at the intron-exon boundaries. They were 
redesigned, when intronic polymorphisms in a primer sequence had been detected, and 
published in Ensembl (http://www.ensembl.org) (145). Methods for genetic analysis and 
sequencing have improved over time. Purification of PCR fragments includes incubation with 
the ExoSap-IT enzyme mix (USB Europe GmbH) and sequencing is performed with the 
fluorescent Big Dye terminator v.3.1 kit (Applied Biosystems). Identical primers were 
initially used for the PCR reaction and consecutive sequencing. They were later redesigned to 
include M13-primer sequences (146). Fragments are size-separated by gel electrophoresis 
and fluorescence is measured using a 3130xl Genetic Analyzer (Applied Biosystems). 
Electropherograms are analysed by visual inspection and with SeqScape Software 3 (Applied 
Biosystems). 
3.3.2 Multiplex ligation-dependent probe amplification (MLPA) 
The MLPA kit SALSA MLPA P055 probe mix (CE-IVD, MRC-Holland) was used to detect 
single gene or single exon deletions or duplications in the PAH gene (Paper IV) (147).  
3.3.3  Reverse transcriptase-PCR (RT-PCR) 
RT-PCR enables the detection of abnormal splicing of the gene (148). Total RNA was 
extracted from blood or fibroblasts from the patients and reverse transcribed to 
complementary DNA (cDNA) by RT-PCR. The cDNA was then multiplied by PCR. Primers 
were designed to bind to sequences within different exons or at the junctions between two 
exons in order to avoid amplification of genomic DNA (Paper II). 
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3.3.4 Bioinformatic programmes 
Variants, not described earlier in a peer-reviewed journal, were analysed with several 
bioinformatic programmes for predicting pathogenicity. 
Programmes used for the prediction of the effect of an amino acid substitution and intron 
variants were: 
 SIFT (http://sift.jcvi.org/) (149) 
 PolyPhen (http://www.bork.embl-heidelberg.de/ PolyPhen/data) (150) 
 PROVEAN (http://provean.jcvi.org) (151) 
 Mutation Taster (http://www.mutationtaster.org/) (152) 
 Fruitfly (http://www.fruitfly.org/seq_tools/splice.html) (153) 
For Paper II allele frequency was obtained from the database ExAC (Exome aggregation 
consortium, http://exac.broadinstitute.org) and variants were checked against dbSNP 
(Database of single nucleotide polymorphism (SNP) for available reference, 
https://www.ncbi.nlm.nih.gov/projects/SNP/). 
Mutation nomenclature follows the guidelines and recommendations of the Human Genome 
Variation Society (http://www.hgvs.org/mutnomen). Novel variants in the PAH and GALT 
gene were validated using the programme Mutalyzer (http://mutalyzer.nl/2.0/). 
 
3.4 ETHICAL CONSIDERATIONS 
For Paper I, ethical permission was not required, since it is a methodological article without 
patient data. 
Ethical permission was received by the Regional Ethical Committee of Stockholm: 
Papers II, IV and V: 2008/351-31 
Papers III: 295/01 and written permission from the patient 
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4 RESULTS 
4.1 PAPER I: GALACTOSEMIA SCREENING WITH LOW FALSE-POSITIVE 
RECALL RATE: THE SWEDISH EXPERIENCE 
During the study period, 43 infants (25 males) were diagnosed with classical galactosaemia. 
One infant died in the newborn period. 
Since the Beutler assay was implemented, in 1984, only patients with GALT deficiency have 
been found. The initial recall level was a GALT activity of 30% or less of the mean activity 
of the samples analysed the same day. The false positive rate was 1/8500, mainly compound 
heterozygous for one Duarte and one classical galactosaemia allele or just heterozygous for 
one classical. The lower recall level (15%) applied from 1992 resulted in a drop in the false 
positive rate to less than one per year, thereby eliminating almost all infants with D/G. 
Another factor which, in some cases, results in a low GALT activity is the presence of EDTA 
in the blood sample. The present protocol, in which all infants with GALT activities ≤10% 
are recalled, has increased the number of false positives recalls to two per year (unpublished 
data).  
All newborns with an activity of less than 15% have been tested for total Gal. Total Gal has 
been above the recall level, >2.0 mmol/l, in all true positive cases, except for two samples 
from younger siblings of patients with GALT deficiency and one newborn who had not been 
fed milk products. 
Independently of the screening method and recall levels, the incidence of GALT deficiency 
has been 1/100 000 since the start. 
 
4.2 PAPER II: HETEROGENEITY OF DISEASE-CAUSING VARIANTS IN THE 
SWEDISH GALACTOSAEMIA POPULATION: IDENTIFICATION OF 
FOURTEEN NOVEL VARIANTS 
In this Paper, the number of patients with galactosaemia identified by screening was 49 (28 
males). An additional nine patients (seven males) are known in the country: three diagnosed 
before the onset of screening, one in 2016 (unpublished data) and five in their home 
countries. The age at diagnosis decreased from an average of eight days before 2008 to four 
days thereafter. 
Molecular analysis of all patients (49 index patients) detected pathogenic variants in all 
alleles. Thirty different GALT variants were identified, out of which 14 are novel (Table 1). 
Thirty-five patients were either homozygous or heterozygous for the common variant, 
p.Gln188Arg. The second most frequent was p.Met142Lys. 
One patient, with an enzyme activity similar to classical galactosaemia in the first and second 
sample, was compound heterozygous for the novel variant p.Ala81Pro and p.Gln188Arg. A 
prolonged incubation with the Beutler test showed that the patient was able to metabolise 
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galactose but at a slower rate than healthy controls. A patient who is compound heterozygous 
for p.[Arg25Pro];[Gln188Arg] exhibited a GALT activity of approximately 3% of normal in 
erythrocytes, as determined with 
14
C
 
-labelled G-1-P as substrate (154). These patients thus 
have attenuated forms of GALT deficiency. 
Amplification of GALT cDNA in a patient homozygous for a synonymous variant affecting 
the last codon in exon 3, p.Pro109= (c.327A>G), revealed four fragments: a normal, two 
longer and one shorter (Figure 1). The patients GALT activity in erythrocytes with 
14
 C
 
-
labelled G-1-P was approximately 1% of normal (Figure 1), indicating that also this patient 
has an attenuated disorder. 
Two deletions in intron 5, c.508-29delT and c.508-2_509delAGAT, activate the same cryptic 
splice site between nucleotides -68 and -67 upstream of c.508. The c.508-29delT variant 
leads to a frame-shift insertion of 22 amino acids with the codon for the 21
st
 amino acid, 
creating a premature stop codon (Figure 2a). The c.508-2_509delAGAT leads to an in frame 
insertion of 21 amino acids (Figure 2b). 
All but three female patients with classical galactosaemia carry GALT variants without rest 
activity. 
 
4.3 PAPER III: PREGNANCY AND LACTATION IN A WOMAN WITH 
CLASSICAL GALACTOSEMIA 
This study was initiated when one of our patients with GALT deficiency chose to breast-feed 
her first newborn. The patient was compound heterozygous for p.[Gln188Arg];[Arg333Trp], 
diagnosed at 8 days of age by NBS. GALT activity in erythrocytes was undetectable. She 
gave birth to two children when she was 30 and 32 years old, respectively. 
The patient showed no signs of late-onset symptoms and her galactitol excretion was elevated 
and blood Gal and G-1-P were below the detection limits for our method. 
A maximum increase of G-1-P to 0.3 mmol/l and 0.25 mmol/l, respectively, was seen after 
delivery. The levels normalised within 3 weeks postpartum and remained below 0.1 mmol/l 
(detection limit) throughout lactation. Galactitol excretion was the same as before the 
pregnancies. Liver transaminases monitored for two weeks post partum remained normal. 
GALT activity in erythrocytes in her first child was 4.7 µkat/kg Hb (10.4 µkat/kg Hb). Blood 
G-1-P was <0.1 mmol/l and galactitol in amnion fluid amounted to 36 µmol/l (0.44-1.2 
µmol/l, (155)). The lactose concentration in her breastmilk was 7g/100g which is in the 
normal range (156). 
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4.4 PAPER IV: THE SPECTRUM OF PAH MUTATIONS AND INCREASE OF 
MILDER FORMS OF PHENYLKETONURIA IN SWEDEN DURING 1965 – 
2014 
During the study, 314 patients (174 males) were diagnosed with PKU/MHP. Six cases with 
co-factor deficiencies have been identified, two of which are from 2015 – 16 (unpublished 
data). Individuals with origins from more than 30 countries are represented in the Swedish 
PKU population. 
The incidence for PKU/MHP was the same during the periods when the recall levels were 
360 µmol/l and 250 µmol/l, respectively. An increase from 1/16 900 to 1/13 500 was seen 
when the recall level was lowered to 180 µmol/l (Table 1). On dividing the study into two 
periods, before and after 1990, the incidence increased from 1/18 300 to 1/14 200 (Table 2). 
The increase seen incidence was almost solely due to an increase in MHP patients from 1/145 
200 to 1/50 000. 
The PPV increased from 0.34 to 0.92 when the Phe/Tyr ratio was included as a marker. The 
ratio excludes patients with liver diseases and infants given intravenous amino acid solution 
who have elevated Phe in the screening sample (Table 3). 
Earlier sampling (age 2 – 3 days), results in lower pre-treatment Phe levels. Classical and 
mild PKU can be difficult to differentiate between since they have similar levels of Phe. In 
earlier sampling, the Phe/Tyr ratio is usually higher in classical than in mild PKU. In MHP 
patients, the Phe levels and Phe/Tyr have already reached their highest levels in samples 
taken on day 2 of age (Figure 1). 
A total of 94 pathogenic variants were detected. The majority were missense variants (60%). 
Five novel variants were identified, associated with classical PKU: c.843-13_843-
10delTTCT, c.970-1G>T and c.1315+5G>A, mild PKU: p.Tyr77His and MHP: 
p.Asp143Val, respectively (Supplementary 2). 
The heterogeneity of pathogenic variants increased after 1990 with 37 variants not being 
detected before (Figure 3). The most frequent variants were the same for the two periods. 
Variants associated with MHP comprise 8.8% of all variants after 1990. The two variants 
with the highest increase after 1990 are p.Arg281Gln and c.1066-11G>A (Figure 2). 
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4.5 PAPER V: PROFOUND BIOTINIDASE DEFICIENCY – A RARE DISEASE 
AMONG NATIVE SWEDES 
Thirteen patients were diagnosed with biotinidase deficiency during 2002 – 2008. An 
additional 16 were identified up to 2016 (unpublished data). Seven children born abroad or by 
means of family screening have also been diagnosed. None of the patients have exhibited any 
symptoms at the time of recall. 
Patients with BD have rarely been diagnosed clinically in Sweden. Newborn screening 
detected the incidence of the disorder as 1/60 000, including profound and partial BD. The 
incidence of profound BD is 1/84 000 based on the number of patients detected to date 
(unpublished data). 
Partial BD is under-diagnosed since the aim of the screening programme is to detect profound 
BD and the recall levels have been adjusted to achieve this goal (134). 
The genetic study included 13 index patients (Table 1). The two most frequently occurring 
variants are p.Asp444His and p.Thr532Met. Seven novel pathogenic variants were found: 
p.Leu83Ser, p.Arg148His, p.Gly445Arg, p.Ile255Thr, p.Asn202Ile, p.Asn402Ser and 
p.Leu405Pro (Table 1 and 2). All novel variants were only detected in one family each. 
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5 DISCUSSION 
This thesis discusses the three first inborn errors of metabolism to be included in the Swedish 
NBS programme: PKU, galactosaemia and BD. We have focused on the screening outcome 
with different methodologies and studied the spectrum of disease-causing variants in the 
disorders. 
5.1 PAPER I 
In the first paper we present the Swedish experience of screening for galactosaemia 
during1967 – 2010. Sweden’s attitude has always been that screening for galactosaemia is 
justified and that it is beneficial for the newborn, but there is no universal agreement about 
our stand point. There are several reasons for the disagreements. In this context, the aim of 
the NBS programme is an important issue. If the intention is to detect all three 
galactosaemias, the screening method of choice is the measurement of total Gal (Gal + G-1-
P), since this is the key metabolite in all disorders. To distinguish patients with GALT 
deficiency from GALK and GALE deficiencies, the programme can combine total Gal with 
the measurement of GALT activity or use it as the second tier for patients with elevated total 
Gal. GALT deficient patients will be detected, and the diagnosis established prior to recall, 
when the methods are combined (total Gal elevated, GALT activity decreased). Use of total 
Gal alone worsens the screening performance. It is elevated in other disorders, e.g. liver 
disease, and can be normal if the infant has not been fed milk prior to testing. The first issue 
will lead to problems involving a high incidence of false positive results and the second may 
lead to false negative results (157, 158). We have experienced the latter problem in younger 
siblings of galactosaemic patients never fed lactose, as well as a patient for which breast-
feeding had not been established. To avoid missing a case, all newborns with an activity of 
less than 10% are recalled independently of the results of total Gal (named the rapid Gal-DH 
test in this Paper). 
Another argument against screening is that newborns with classical galactosaemia exhibit 
symptoms shortly after birth and will be diagnosed anyway. This is true, but galactosaemia is 
a rare disorder and the first symptoms, vomiting and jaundice, are unspecific and, in reality, 
the lack of NBS will delay the diagnosis and the starting of a lactose-free diet, which may 
even lead to a sepsis and death. This problem is avoided with NBS, in which the GALT 
enzyme activity is measured. The screening can be performed early on, if necessary, already 
on cord blood, and the performance of the method is not dependent on galactose ingestion. 
We have shown that with a well-functioning screening programme and early sampling, the 
newborn with galactosaemia can be on treatment within one week of age. The child will 
exhibit signs of the disease, such as elevated liver enzymes, but avoids the more severe 
symptoms. One infant has died since the start of screening, while there are only four known 
living patients born before NBS in Sweden. Early detection does not prevent long-term 
complications, which has been an additional argument against screening. Unfortunately, there 
is no clear association between genotype, initiation of treatment and compliance with later 
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sequelae. In the Swedish galactosaemia population, in which treatment was started early, 
some patients have avoided most of the complications whereas other patients are more 
severely affected (unpublished data). 
Duarte galactosaemia has been considered to be a benign disorder, but recently published 
studies, although with small cohorts, indicate that D/G patients, as a group, may experience 
subtle developmental deficits during childhood (159, 160). 
The aim of the Swedish NBS programme is, however, to detect newborns with the classical 
disease form and to avoid identifying infants with the D/G. This has been achieved by 
continuous evaluation of the performance of the programme. 
The lower recall level, implemented in 1992, decreased the false positive rate to less than one 
newborn a year, but since the change to earlier sampling time in 2008, it is two per year. Half 
of the false positive samples are from newborns with D/G and the rest are from infants whose 
blood sample had contained EDTA. Samples with GALT activity below the recall level and 
taken at 48 – 72 hours are recalled regardless of the results for total galactose. Regardless of 
screening method, the incidence of classical galactosaemia has been 1/100 000, which is 
lower than the reported incidence of approximately 1/23 000 – 1/44 000 in Western Europe 
(74). We are not aware of any missed cases. 
The present approach for galactosaemia screening in Sweden has resulted in a well-
functioning programme. Compared to other programmes, we do not struggle with high false 
positive rates and we diagnose few infants who may not be in need of treatment.  
 
5.2 PAPER II 
In GALT deficient patients, the most common cited variant is p.Gln188Arg, and our 
population is not an exception (90). Eighteen patients were homozygous for the variant and 
17 were heterozygous. The number of homozygous patients is, however, decreasing and the 
group of pathogenic variants is becoming more heterogeneous. 
The method for genetic studies used before Sanger sequencing became routine, was 
restriction fragment length polymorphism (RFLP). With RFLP only one variant at a time can 
be detected (161). This is convenient if a variant occurs at a high frequency, since it includes 
less labour than Sanger sequencing. This method was used in the first nine GALT patients to 
be genotyped in Sweden (Wadelius C, personal communication) and five were homozygous 
for the variant. If this method should have been used in the nine latest diagnosed patients, 
only one patient would have been fully genotyped and two found to be heterozygous. 
The genetic analysis revealed a total of 30 different variants. Variants not previously reported 
to the GALT databases in HGMD® Professional 2016.2 and at Arup laboratories 
(http://www.arup.utah.edu/database/galt/GALT_welcome.php), were considered novel. Of 
the 14 novel variants detected in our population, three are of less severity, of which two are 
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found in dbSNP: p.Leu71Phe (rs143994870) and p.Ala81Pro (rs111033665) and one has not 
been reported: p.Arg25Pro. The latter two were found in patients detected in NBS, while 
p.Leu71Phe was detected in an unaffected relative through family screening. 
Several synonymous variants have been reported in the GALT gene, but only one has earlier 
been proven to be disease-causing. The patient harbouring the synonymous change, 
p.Pro109= in the last codon of exon 3, is therefore of special interest. The presence of four 
fragments after amplification of GALT cDNA, of which one fragment was of normal length, 
indicates that the variant leads to leaky splicing. The patient has approximately 1% of normal 
GALT activity, probably due to the presence of the normal transcript. No other alterations in 
the GALT gene were detected, indicating that the phenotype of the patient was solely due to 
the p.Pro109= variant. This emphasises the importance of not neglecting synonymous 
variants, especially if they are near the splice site areas. 
The Duarte variant, p.Asn314Asp, occurs at an international frequency of 9.2% (ExAC) and 
it is not uncommon that the variant occurs in cis with other GALT variants (162). In our 
population, we detected two patients carrying a cis variant on one allele each, of which one 
was in cis with the novel variant p.Arg33Cys. 
Measurement of GALT activity for assessment of Mendelian inheritance can be inconclusive. 
We have identified four GALT alleles in a family with an inconclusive pattern of GALT 
activity in erythrocytes from family members (Table 4). Three of the four variants have only 
been described in this family: p.Leu71Phe, p.Glu160del (de novo allele) and 
p.Gln353_Ala354ins18 whereas the fourth was the p.Asn314Asp allele. One child has 
classical galactosaemia, while the other has Duarte galactosaemia. This shows that, in some 
cases, sequencing of the whole gene in all family members is required for a correct 
diagnosis. 
  
5.3 PAPER III 
The majority of females with classical galactosaemia have reduced fertility due to premature 
ovarian insufficiency (POI). Twenty years after the introduction of NBS, it was noted that 
hypergonadotropic hypogonadism occurred at a high frequency in females, but not in males 
(163-165). What mechanisms are involved has not been clarified (166). 
Disorders included in NBS are unknown to the average citizen and galactosaemia is not an 
exception. Parents of a newborn suspected to have or has been diagnosed with the disorder 
will most likely Google the disease. There they read about the long-term complications and 
that the majority of girls develop POI. The main opinion among physicians has been that 
most females with galactosaemia will never be able to become mothers. In our population, 
three out of eight women (37%), over the age of 25, have given births (unpublished data).  
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Another issue is the earlier recommendation in the literature that women with classical 
galactosaemia should not breast-feed their infant because of the risk of accumulation of toxic 
metabolites (167). We had the opportunity to follow one woman through two uneventful 
pregnancies. We discouraged her from breast-feeding, but she insisted. This choice changed 
the recommendations for this group of patients. Galactose metabolites and liver enzymes 
were monitored during her pregnancies and post partum. Liver enzymes remained normal, 
but the same increase in G-1-P, as described in the literature, was noticed. However, 2 – 3 
weeks post partum, the levels returned to the same as prior to the pregnancies. The findings in 
our patient have been confirmed by other researchers. The outcome for female patients with 
regard to motherhood seems to be better than hypothesised earlier (168). 
5.4 PAPER IV 
In Paper IV, the 50 years of screening for PKU was divided into two periods: before and after 
1990. This point in time was chosen because the immigration from non-Nordic countries 
increased greatly from this time (www.scb.se). There has been an increase in the incidence of 
MHP in Sweden and we hypothesised that this was caused by the lower screening recall level 
for Phe since 2003 (Table 1). This could not, however, be confirmed since the majority of 
recalled patients with MHP had Phe values above the recall level used before the change in 
2003. The increase in patients with milder severities was caused by the immigration. Patients 
from non-Nordic countries have a higher frequency of mild pathogenic variants than native 
Swedes (169). 
There has been a tendency to lower the recall levels for Phe internationally. This will increase 
the detection of MHP infants not in need of treatment and the incidence of false positive 
cases (170, 171). With this development, there is a risk that the situation for PKU will 
encounter the same dilemma, as in galactosaemia and biotindase screening, where we identify 
infants about whom we are not certain if they need treatment or not. 
The native Swedish population has become more and more mobile the past decades, which is 
reflected in fewer Swedish patients being homozygous for common pathogenic variants. The 
spectrum of pathogenic variants detected in our PKU patients has changed, during recent 
decades, to become more heterogeneous, now including 94 unique variants (Supplementary 
2). Of these, only 32 have been found in both of the two populations diagnosed before and 
after 1990 (Figure 3). The variants with the highest frequencies have been the same for the 
two periods, p.Arg408Trp, c.1305+1G>A and p.Tyr414Cys, although a decline has been seen 
in the latter period (Figure 2). MHP has been rare in Sweden but it increased three fold with 
the immigration and now occurs at an incidence of 1/50 000. Common MHP variants are 
p.Ala300Ser, p.Ala403Val, p.Asp415Val and p.Glu390Gly, all having been well described in 
the literature (Figure 2) (172-175). 
The sampling time of the NBS test has been put forward continuously from 5 – 6 days of age 
to the present 48 hours (176). In Sweden, we recommend the test to be taken at age 48 – 72 
hours. At this age, most of the newborns are catabolic, which optimises the chances to detect 
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many of the inborn errors of metabolism included in the programme. The Phe level in the 
screening sample has guided the clinicians at the start of treatment of a suspected PKU case. 
In an investigation, where we compared Phe levels and Phe/Tyr ratios taken at different ages, 
we could see that the change in sampling time has had an impact on the results. The 
concentration of Phe increases only slightly in mild PKU and dramatically in classical 
patients, while the maximum pre-treatment values in MHP are already reached at age 2 – 3 
days. The close to equal Phe levels in mild and classical PKU patients on day 2 can lead to 
misinterpretations of the severity (Figure 1a). Pre-treatment Phe/Tyr ratios in MHP and mild 
PKU patients do not change with age at sampling, while an increase is seen in classical PKU 
patients (Figure 1b). The Phe/Tyr ratio, together with the Phe values, are better for predicting 
the severity of disease than Phe values alone in samples taken before 4 days of age. 
PKU screening is a success. Patients doomed to develop mental disabilities prior to NBS are 
now given the chance to live normal lives, with the exception of the cumbersome diet. 
Infants with co-factor deficiencies can be detected in the programme, but they can be missed 
because of low Phe levels at the time of sampling. These disorders have been extremely rare 
in Sweden, with only three cases diagnosed before 2014, one of which was not recalled in the 
screening. During the past two years, however, three patients, two with PTPS deficiency and 
one with GTPCH deficiency, have been diagnosed, one of which had Phe levels far below the 
recall level (unpublished data). Only time will tell if the latter three cases are coincidental or 
if they are a sign of co-factor deficiencies being more common than anticipated. 
5.5 PAPER V 
Biotinidase deficiency was an almost unknown disorder in Sweden until it was included in 
the NBS programme in 2002. A pilot programme 10 years earlier had only detected one 
patient among 215 000 screened newborns, although the world wide incidence was known to 
be approximately 1/60 000 (127). 
Undiagnosed patients are at risk of developing symptoms which can be vague and there are 
several differential diagnoses, including mitochondrial disorders (129). Each year, the 
laboratory receives samples from patients suspected of having the disorder. Until now, none 
of them have turned out positive. There can be two reasons for this: the diagnosis is missed 
due to the absence of classical symptoms or patients exhibit symptoms, but physicians do not 
connect them with the disorder. 
The group of patients with BD has increased to 29 since this article was published. Lowering 
the recall level to ≤20% has had the desired effect on the performance. Only 25% of the 
confirmed BD patients have had partial BD, compared to more than 50% at the time of the 
article. Interestingly, an additional seven BD patients have been diagnosed through the 
screening of immigrant/adoptive children. All but one has had profound BD and none, to our 
knowledge, has exhibited symptoms at the time of recall. The same low incidence of 
profound BD is seen after the article was published (unpublished data). It is not possible to 
calculate the total incidence of BD since we only occasionally detect infants with partial BD. 
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The most common pathogenic variant in our population is p.Thr532Met. It is a variant 
associated with profound BD, but with uncertain severity. Symptoms have been described in 
several patients, and homozygosity for the variant appears to be associated with mild and/or 
late onset of symptoms (126, 177) 
Analyses of the BTD gene have revealed that the pathogenic variants differ between clinically 
diagnosed patients and patients ascertained by NBS (137). One could speculate, as to whether 
NBS leads to over-diagnosis. In our group of patients, all identified by NBS, the majority of 
patients carry at least one variant described earlier only in patients identified by NBS. These 
patients may have never been at risk of developing symptoms regardless of treatment. The 
same phenomenon has been described in other disorders included in NBS programmes e.g., 
MCAD and VLCAD deficiencies (178, 179). 
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6 CONCLUSIONS 
This study covers data from the National Swedish Neonatal Screening Programme for PKU, 
galactosaemia and BD from the start until today. During this time, the methods for PKU and 
GALT have improved up to the present very high positive predictive values: 0.92 and 0.54, 
respectively, and high sensitivity (Papers I and IV). 
With regards to PKU and GALT deficiency, genetic variants common in other European 
countries and the USA are also seen in our population. A change in the spectrum has been 
observed since 1990 when the number of immigrants from Non-Nordic countries increased. 
The incidence of 1/100 000 for GALT deficiency has, however, been the same since the start 
of screening in 1967 (Paper I and II). 
In Paper III, we show that women with classical galactosaemia, in contrast to earlier 
recommendations, can safely breast-feed their babies. 
The spectrum of disease-causing variants in the PAH gene has become more heterogeneous, 
with an increase in less severe variants (Paper IV). 
Inclusion of biotinidase deficiency in NBS (since 2002) has shown that the incidence of 
profound BD is similar to other European countries. The spectrum of disease-causing variants 
in our screened cohort differs from that in clinically diagnosed patients (Paper V). 
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7 CLINICAL IMPLICATIONS 
The improvements in the screening methods for PKU and galactosaemia have resulted in 
lower false positive recall rates, without loss of sensitivity. Fewer families with healthy 
infants are recalled and disturbed in the sensitive neonatal period. Inclusion of biotinidase in 
the programme has resulted in early detection and treatment of this almost unrecognised 
disorder, with only two cases diagnosed in Sweden before screening. 
We have balanced the recall levels in the screening for galactosaemia and BD to detect only 
children with classical galactosaemia and profound BD. The aim is to avoid the detection of 
partial forms which most probably do not require treatment. 
Including the ratio Phe/Tyr as a second marker increases the PPV for NBS for PKU. 
Screening methods where Phe is used as the single marker will not differentiate between true 
positive PKU cases and newborns with liver disease and/or on treatment with intravenous 
amino acid infusion. Earlier sampling has led to lower Phe values in the first screening 
sample, thereby complicating the prediction of disease severity. We have shown that the ratio 
Phe/Tyr is lower in patients with mild PKU than in those with classical PKU even when the 
Phe values are in the same range. This information is important for initiating treatment. 
The results in Paper III show that women with classical galactosaemia can breast-feed their 
newborns without any complications. Our results have been confirmed by other researchers. 
The recommendation for breast-feeding is now the same for women with GALT deficiency 
as for healthy women. 
All three diseases are caused by several different disease-causing variants. Sanger sequencing 
covering all coding exons and exon/intron boundaries is therefore a better strategy for genetic 
analysis than a panel of pathological variants. 
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8 FUTURE RESEARCH 
The development of new biochemical and genetic methods has been fantastic during the last 
few decades. It is now possible to determine the concentrations of small molecules, such as 
amino acids, fatty acids and proteins, simultaneously in small volumes of blood (140). The 
whole genome can be sequenced within hours with massive parallel sequencing – next-
generation sequencing (180). 
Technically almost any known disorder can be included in a screening programme. It is now 
the clinical usefulness, side effects such as identification of healthy carriers, and other ethical 
aspects, as well as costs that have to be carefully considered when a new disease is to be 
included in a screening programme (181). 
In the USA, it is recommended to include many diseases which we are hesitant to add to our 
programmes in Europe. Some of them are hardly treatable, whereas others have a clinical 
course that makes it very difficult to know when to implement a treatment that can be hard on 
the patient and expensive for society (182). 
An example of the former is the lysosomal disease, infantile Krabbe, in which early treatment 
with bone marrow transplantation is not curative, but slows down the progression to early 
death (183). The latter problem is the case in Fabry disease, which often presents with 
symptoms late in the first decade in boys and later in girls, and is treated with biweekly 
infusions containing the missing enzyme (184). 
Many countries screen for cystic fibrosis (176) and this disorder is under evaluation led by 
the Swedish Board of Health and Welfare. We are presently at the end of a three-year trial 
with neonatal screening for primary immunodeficiency disorders in Stockholm County, and 
hope to obtain permission to include this group of disorders in the programme. 
We are planning for two research projects in the laboratory: 
Screening for galactosaemia has been performed for more than 50 years. It has still not been 
confirmed, however, if D/G patients require treatment (160, 185). We have records, at the 
screening laboratory, of over 80 patients with D/G detected by NBS during 1986 – 1991. We 
are planning a retrospective, population-based study using data derived from nationwide 
Swedish registries. The aim of the study is to record mortality, morbidity, fertility and levels 
of education in the group and matched controls. 
GALK deficiency is rare in most countries but a founder effect has been described in the 
Romani population (186). The present method for galactosaemia screening in Sweden does 
not detect GALK deficiency. Three patients were detected when the bacterial inhibition assay 
was used. An additional three patients were diagnosed and verified genetically in 2012, 
because of bilateral cataracts. We now suspect that patients with the disorder are undiagnosed 
and plan a collaborative study using the Swedish Child Cataract Registry to answer this 
question. 
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9 SVENSK SAMMANFATTNING 
PKU-provet innebär att nyfödda undersöks för sällsynta, men allvarliga, behandlingsbara 
sjukdomar. Sjukdomarna ger oftast inga uppenbara symtom direkt vid födelsen. 
Målsättningen med nyföddhetsscreeningen är att hitta nyfödda med någon av de 24 
sjukdomar som ingår i PKU-provet innan barnen hunnit blir sjuka. 
I den här avhandlingen beskriver vi hur nyföddhetsscreeningen för sjukdomarna 
fenylketonuri, galaktosemi och biotinidasbrist har utvecklats i Sverige. Vi har undersökt hur 
de olika metoder som har använts under åren har påverkat utfallet. Nästan alla patienter som 
har diagnostiserats med någon av sjukdomarna har genomgått genetisk analys och där har vi 
undersökt vilka förändringar i respektive gen som är orsak till sjukdomen. 
Sammanställningen av galaktosemiscreeningen visar att Sverige har det lägsta antalet falskt 
positiva larm bland publicerade studier, samt att våra patienter med klassisk galaktosemi får 
en tidig diagnos vilket är betydelsefullt för överlevnad (Artikel I). 
Resultatet av de genetiska studierna för galaktosemi visar att den vanligaste sjukdoms-
framkallande genetiska förändringen i GALT-genen i Sverige är p.Gln188Arg, och den är 
också vanligast i övriga världen. Totalt hittades 28 olika varianter av vilka 14 inte var 
beskrivna tidigare (Artikel II). 
Rekommendationen i litteraturen har varit att patienter med galaktosemi avråds från att amma 
sina barn. Vi hade möjlighet att följa en patient under två graviditeter. Det visade sig att 
patientens galaktosmetaboliter normaliserades 2 – 3 veckor efter förlossningen. Efter att 
resultatet har publicerats har andra forskargrupper bekräftat att det är fullt möjligt för 
patienter med galaktosemi att amma sina barn (Artikel III). 
Totalt har 314 patienter fått diagnosen PKU under perioden 1965 – 2014. I patientgruppen 
har vi sett en ökning av mildare former av PKU. Antalet sjukdomsframkallande varianter i 
PAH-genen är större i gruppen födda efter 1990 vilket tyder på att PKU-populationen har 
blivit mer heterogen (Artikel IV). 
Sammanställningen av screeningen för biotinidasbrist visar att sjukdomen är lika vanlig i 
Sverige idag som i övriga Europa, 1/60 000 nyfödda. De allra flesta barnen har sitt ursprung 
från länder utanför Norden. De genetiska studierna visar att ett fåtal varianter är vanlig men 
också att inte tidigare beskrivna varianter förekommer (Artikel V). 
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